Navigation Links
Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
Date:1/24/2010

2009.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.

Forward-Looking Statement

This release contains forward-looking statements interpreting the results of the Company's Phase 2 clinical trial of picoplatin in metastatic colorectal cancer and describing the Company's regulatory and partnering strategies with respect to such product candidate. Actual results and events may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties inherent in the Company's business, including, but not limited to, the potential safety, efficacy and commercial viability of picoplatin; the risk that the Company's additional analyses of data from clinical trials of picoplatin may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted trials, including the Phase 2 trial described in this press release; the results and timing of the Company's discussions with the FDA; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; the Company's ability to attract and retain key personnel and enter into strategic partnerships on favorable terms, or at all; competition from third parties; the Company's ability to preserve and protect its intellectual property rights; the Company's dependence on third-party manufacturers, suppliers and other contractors; changes in technology, government regulation a
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  AliveCor, Inc. announced today ... (FDA) has granted the company clearance for ... the most common form of cardiac arrhythmia. ... if patients are experiencing AFib through real-time ... phone based AliveCor® Heart Monitor, so physicians ...
(Date:8/21/2014)... , Aug. 21, 2014 Professional Compounding ... paediatric medicine by awarding the three best scientific ... initiative (EuPFI) conference . The Formulating Better ... 18 in Athens, Greece , ... students and professionals, from which three winners will ...
(Date:8/21/2014)... CYBX ) today announced results for the quarter ...   Operating results for the first quarter of ... and other achievements, include: , Worldwide net product sales ... international net sales of $13.2 million, an increase of 14.5% ... sales reached a new high of $58.8 million, an increase ...
Breaking Medicine Technology:AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16
... Sigma-Aldrich® (Nasdaq: SIAL ) today announced ... Inc., a Berks County, PA. -based provider of ... Animals ( www.aceanimals.com ), a commercial rodent breeder established ... services, and will operate as part of Sigma Advanced ...
... NATICK, Mass. and ATLANTA , ... BSX ) today announced results from an analysis ... assessing the impact of diabetes on clinical and angiographic ... Express2™ Paclitaxel-Eluting Stent System or the Express® ...
Cached Medicine Technology:Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 2Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 3Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 4Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 5Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 6Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 7Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 2Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 3Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 4Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 5Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 6
(Date:8/21/2014)... San Diego, CA (PRWEB) August 21, 2014 ... this year, is a short but powerful collection of ... meant to uplift and inspire other budding entrepreneurs on ... honored and proud to announce the inclusion of President ... and insight from highly successful and self-made celebrities such ...
(Date:8/21/2014)... ERT, a leading global solution ... endpoint data collection, today opened registration for ... Product Value with Optimized Endpoints. The ... developers to network with leading researchers as ... implementing, and justifying effective strategies for collecting ...
(Date:8/21/2014)... Early diagnosis of diabetic peripheral neuropathy is important ... group at the Fourth Affiliated Hospital of Kunming ... sought to establish a sensitive index for nerve ... neuropathy in 500 patients with diabetes mellitus. Nerve ... longer, sensory nerve conduction velocity was slower, and ...
(Date:8/21/2014)... 21, 2014 The ... Vascular Devices Market by Angioplasty Balloon ... (IVUS, OCT), IVC Filter (Retrievable), Endovascular ... analyzes and studies the major market ... U.S. and Canada. , Browse 108 ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Artisan Business ... & Investment Exploratory Delegation to southern China October 12-19, ... to explore the rapid growing cities of Shenzhen and ... will have the rare opportunity to meet with major ... during a short weeklong time frame. , The ...
Breaking Medicine News(10 mins):Health News:Earth Source Organics President Audrey Darrow Featured in New David Mullings Book 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5Health News:Artisan Business Group announces 2014 EB-5 Investment Trade Mission to China 2
... June 5 (HealthDay News) -- The human body has two ... and the "good" brown kind that burns them. Now, researchers ... fat to help people lose weight. "We are now ... treating obesity and diabetes," study lead author Dr. Aaron Cypess, ...
... -- ASCO Abstract #CRA9015. Flaxseed provides no benefit in ... and postmenopausal women, according to a Mayo Clinic ... (NCCTG) study. The randomized, placebo-controlled study was conducted on ... no statistically significant difference in mean hot flash scores ...
... a study that included nearly 18,000 children who had cancer, ... associated with a subsequent primary neoplasm (a new tumor) at ... neoplasms (related to the genital or urinary tract organs), according ... JAMA , a theme issue on cancer. The study is ...
... a woman,s skin wrinkles are during the first few years ... will be presented Monday at The Endocrine Society,s 93rd Annual ... the skin may offer a glimpse of the skeletal well-being, ... reproductive endocrinologist and associate professor at Yale School of Medicine, ...
... HealthDay Reporter , FRIDAY, June 3 (HealthDay News) -- U.S. ... little chance the deadly new strain of E. coli bacteria ... impact here. "This outbreak has not affected the ... Administration,s Regional Operations, said during a Friday afternoon news conference. ...
... -- A mutant gene long thought to accelerate tumor ... of malignant cells, showing promise for novel cancer therapies, ... will be presented by Mayo Clinic researcher Honey Reddi, ... Dr. Reddi,s discovery could have widespread implications in cancer ...
Cached Medicine News:Health News:Brown Fat Cells May One Day Help Combat Obesity 2Health News:Mayo Clinic: Flaxseed no cure for hot flashes during breast cancer or menopause 2Health News:Childhood cancer survivors at increased risk of certain tumors in middle-age 2Health News:Childhood cancer survivors at increased risk of certain tumors in middle-age 3Health News:Severity of facial wrinkles may predict bone density in early menopause 2Health News:Officials: U.S. Not Affected by European E. Coli Outbreak 2Health News:Officials: U.S. Not Affected by European E. Coli Outbreak 3Health News:Fighting cancer with cancer: Mayo Clinic finds promising use for thyroid cancer gene 2
Desmarres Retractor Size 4...
Desmarres Lid Retractor thin solid blades. Size 2....
... system introduces a new level ... microsurgical instrumentation. It has an ... with advanced microcomputer control of ... operate with a full range ...
Multiple Modulation Phaco (MMP) programmability with eight surgeon settings for maximum versatility. The combination of the peristaltic power balanced pump and the piezoelectric handpiece results in ...
Medicine Products: